Test Price
3,000 AEDโ Home Collection Available
Myeloid Tumor Panel Genetic Test in UAE | 3,000 AED | NGS Precision Oncology
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% diagnostic sensitivity achieved via ISO 9001:2015 accredited NGS processing, ensuring clinically actionable insights for your treating hematologist-oncologist.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM, 7 days a week.
- Clinical Guidance: Complimentary post-test telephonic counseling from a certified genetic counselor to bridge complex genomics with your personalised care plan.
- Insurance Support: Direct billing verification and pre-authorization assistance via WhatsApp: +971 54 548 8731.
The Myeloid Tumor Panel delivers definitive molecular classification of Acute Myeloid Leukemia, Myelodysplastic Syndromes, and Myeloproliferative Neoplasms, enabling targeted therapy selection and minimal residual disease monitoring. All processing occurs within DNA Labs UAE, a DHA-licensed facility (License No. 1143).
Test Overview & Methodology
The Myeloid Tumor Panel Genetic Test is a comprehensive next-generation sequencing assay designed to detect somatic and germline mutations across 37 critical genes, including ASXL1, TP53, FLT3, IDH1, IDH2, RUNX1, TET2, DNMT3A, SF3B1, SRSF2, U2AF1, CEBPA, NPM1, KIT, KRAS, NRAS, JAK2, CALR, MPL, EZH2, STAG2, BCOR, BCORL1, ZRSR2, RAD21, SMC1A, SMC3, PHF6, NF1, PTPN11, CBL, SETBP1, ETNK1, GATA2, WT1, IKZF1, and MYD88, implicated in myeloid malignancies. This test provides a definitive molecular classification of Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), and Myeloproliferative Neoplasms (MPN) to guide personalized targeted therapy selection and minimal residual disease monitoring according to international oncologic consensus guidelines.
| Test Parameter | Our Test: Myeloid Panel NGS | Closest Alternative: Single-Gene PCR |
|---|---|---|
| Methodology | Advanced NGS (Liquid-Phase Capture + Bioinformatics Pipeline) | Quantitative Real-Time PCR |
| Genes Analyzed | 37 Genes (Comprehensive Multi-Gene Panel) | 1โ3 Genes (Limited Scope) |
| Variant Detection | SNVs, Indels, CNVs (Broad Genomic Coverage) | Specific Known Mutations Only |
| Turnaround Time | 3 to 4 Weeks (Definitive Comprehensive Report) | 1โ2 Weeks (Requires Follow-up Reflex Testing) |
Physician Insight & Safety Protocols
"This comprehensive NGS panel functions as a diagnostic compass for myeloid malignancies, yet each variant must be rigorously correlated with the patient's full clinical phenotype. Mutations such as TET2 or DNMT3A may reflect age-related clonal hematopoiesis of indeterminate potential rather than overt neoplasia. My team curates every finding against the complete blood count, peripheral smear, and bone marrow histology to deliver an integrated molecular interpretation. Patients should understand this test as a critical guide, not a standalone diagnosis."
โ Lina Osama Zaki Quteineh, Consultant Medical Genetics (DHA Registration ID: 9294403)
Critical Clinical Safety Notice โ Medication Continuity
Do not discontinue, modify, or change the dosage of any prescribed medication, including anticoagulants, hypomethylating agents, or targeted chemotherapy, without explicit instruction from your treating consultant. This genetic test provides diagnostic and prognostic information and must not be used independently to make acute therapeutic changes. All clinical decisions require oversight by your registered hematologist-oncologist.
Patient Safety Shields: Exclusion Criteria & Emergency Red Flags
- Exclusion Criteria: Hemodynamic instability requiring immediate critical care; active severe bleeding (WHO Grade โฅ3) precluding safe phlebotomy; known skin integrity issues at the venipuncture site.
- Emergency Red Flags (Seek Immediate Emergency Care, not a scheduled test): Sudden onset of uncontrollable bleeding, acute fever with rigors and neutropenia (Absolute Neutrophil Count < 0.5 x 10โน/L), new-onset confusion, or shortness of breath at rest.
- Sample Integrity Note: Patients who have received a packed red blood cell or platelet transfusion within the 48 hours prior to collection should be noted; this does not contraindicate the test for DNA extraction but may affect circulating blast assessment.
Patient FAQ & Clinical Guidance
1. What specific genetic mutations does this panel detect, and why does the test require 3โ4 weeks?
This test analyzes 37 critical genes โ including FLT3, IDH1/2, TP53, NPM1, CEBPA, RUNX1, and SF3B1 โ providing comprehensive diagnostic clarity for myeloid neoplasms. The exact turnaround time of 3 to 4 weeks is required because our methodology involves DNA extraction, complex library preparation, high-depth next-generation sequencing on certified platforms, and a multi-step bioinformatics pipeline followed by clinical variant curation by a molecular geneticist to filter out benign polymorphisms and confirm actionable mutations. This rigorous process ensures a definitive, clinically actionable report.
2. Can I use an FTA card for home collection, and will it affect the test's diagnostic sensitivity?
Yes, we accept one drop of blood on a specialized FTA card, which immediately stabilizes DNA at ambient temperature for transport. This method yields highly purified genomic DNA suitable for NGS, and our internal validation studies confirm it maintains >99% sensitivity compared to standard venipuncture into EDTA tubes, provided the collection procedure is followed correctly during our VIP Mobile Phlebotomy service. This is the preferred method for international or remote patients. Our temperature-controlled cold-chain logistics ensure sample integrity from your location to our Dubai Healthcare City laboratory.
3. How should I interpret a variant of uncertain significance (VUS) in my report?
A variant of uncertain significance means the genetic change identified has insufficient evidence in current medical literature to be classified definitively as benign or pathogenic. Our laboratory employs a comprehensive evaluation using population databases, in silico prediction tools, and segregation analysis. If a VUS is reported, you will receive a complimentary telephonic consultation with our genetic counselor, who will explain the finding, discuss the possibility of reclassification as new evidence emerges, and coordinate with your treating oncologist to determine if functional studies or family segregation testing is warranted.
UAE Regulatory & Data Privacy Adherence
Your genomic data is fully anonymized, encrypted, and processed on-shore in accordance with:
- Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) โ governing the collection, processing, and storage of your personal and genetic information.
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields โ regulating the security and confidentiality of electronic health records and genomic databases.
- Federal Decree-Law No. 4 of 2016 on Medical Liability โ ensuring that all clinical testing, patient consent protocols, and safety standards meet the highest legal benchmarks.
Genomic information is never shared with employers, insurers, or third parties without explicit written patient consent or a valid court order. For minors, mandatory parental or guardian consent is documented and archived in compliance with UAE federal regulations. Our DHA-licensed facility (License No. 1143) at Dubai Healthcare City maintains strict access controls and audit trails for all patient data.
Clinical & Logistical Metadata
| Test Name | Myeloid Tumor Panel Genetic Test |
| Price (AED) | 3,000 |
| Turnaround Time | 21โ28 Calendar Days (3โ4 Weeks) |
| Sample Type / Matrix | Peripheral Whole Blood (EDTA or FTA Card) or Bone Marrow Aspirate |
| Methodology Used | Next-Generation Sequencing (NGS) โ Liquid-Phase Hybrid Capture with Multi-Platform Bioinformatics Pipeline |
| ICD-10-CM Code | C92.0 (Acute Myeloid Leukemia) |
| LOINC Code | 92833-1 (Myeloid disorders gene panel by NGS) |
| DHA Facility License & Laboratory Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
ุฏุนู ุซูุงุฆู ุงููุบุฉ ู ุชุงุญ
ุงูุชุญูู ู ู ุงูุชุบุทูุฉ ุงูุชุฃู ูููุฉ
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
ุชููู ุนู ุงูุชุฎู ูู. ุฃุฑุณู ุตูุฑุฉ ู ู ุจุทุงูุฉ ุงูุชุฃู ูู ููุตูุฉ ุงูุทุจูุจ ุฅูู ูุฑูู ุงูุชุญูู ุงูู ุนุชู ุฏ ู ู ููุฆุฉ ุงูุตุญุฉ ุจุฏุจู ุนุจุฑ ุงููุงุชุณุงุจ. ุงุญุตู ุนูู ุชุญุฏูุซ ุงูุญุงูุฉ ูู ุฏูุงุฆู.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians